Expression of 17 β -hydroxysteroid dehydrogenase types 1, 2, 3 and 4 in the human temporal lobe

B Stoffel-Wagner, M Watzka, S Steckelbroeck, J Schramm¹,
F Bidlingmaier and D Klingmüller

Department of Clinical Biochemistry, University of Bonn, 53105 Bonn, Germany

¹Department of Neurosurgery, University of Bonn, 53105 Bonn, Germany

(Requests for offprints should be addressed to B Stoffel-Wagner, Institut für Klinische Biochemie, Universität Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany)

Abstract

Sex steroid hormones exert important biological effects on the brain. Moreover, an extensive sex steroid metabolism occurs in the brain. In sex steroid metabolism 17 β -hydroxysteroid dehydrogenases (17 β -HSDs) play essential roles in catalyzing the final steps in androgen and estrogen biosynthesis. Recently four types of human 17 β -HSDs and a pseudogene of the type 1 isoform were identified. To date, 17 β -HSD has not been extensively studied in the human brain. Therefore, we investigated the mRNA expression of the four isozymes of 17 β -HSD as well as the pseudogene of the type 1 isoform in the human temporal lobe to determine the predominant isoforms and, moreover, to elucidate the existence of possible sex and age differences. We studied biopsy materials from the temporal lobe of 34 women, 32 men and 10 children. Quantification of different mRNAs was achieved by competitive reverse transcription-PCR. 17 β -HSD 1, 17 β -HSD 3 and 17 β -HSD 4 were expressed in the human temporal lobe of

children and adults, whereas 17 β -HSD 2 and the pseudogene of 17 β -HSD 1 were not expressed. In adults, 17 β -HSD 3 and 17 β -HSD 4 mRNA concentrations were significantly higher in the subcortical white matter (17 β -HSD 3: $14\,591 \pm 3457$ arbitrary units (aU), mean $\pm$ s.e.m.; 17 β -HSD 4: 1201 ± 212 aU) than in the cortex (17 β -HSD 3: 5428 ± 1057 aU, $P < 0.0002$; 17 β -HSD 4: 675 ± 74 aU, $P < 0.004$). 17 β -HSD 1 concentrations did not differ significantly between the white matter (3860 ± 1628 aU) and the cortex (2525 ± 398 aU) of adults. In conclusion, the present study demonstrates the expression of 17 β -HSD 1, 3 and 4 mRNAs in the human temporal lobe. Together with CYP19_{AROM} and 5 α -reductase, known to be expressed in the human brain, the expression of 17 β -HSD 1, 3 and 4 mRNAs indicates the major importance of local steroid biosynthesis in the brain.

Journal of Endocrinology (1999) **160**, 119–126

Introduction

The brain is an important target organ of sex steroid hormones and an extensive sex steroid metabolism including aromatization and 5 α -reduction occurs in several regions of the brain (Martini & Melcangi 1991, Lephart 1993, Naftolin 1994, Stoffel-Wagner *et al.* 1998a,b). Specific receptors for sex steroids have been identified in several regions of the brain, through which sex hormones could effect a genomic response (Sholl *et al.* 1989, Simerly *et al.* 1990).

In sex steroid metabolism 17 β -hydroxysteroid dehydrogenases (17 β -HSDs) catalyze the final steps in androgen and estrogen biosynthesis, thus playing a crucial role in the biosynthesis and inactivation of sex steroid hormones.

Recently four types of human 17 β -HSDs were identified and their structure elucidated. Type 1 17 β -HSD, which is expressed in placenta, granulosa cells and a number of other tissues, primarily catalyzes the inter-

conversion of the weak estrogen estrone (E1) and the strong estrogen estradiol (E2) with a predominance of the reductive pathway (Peltoketo *et al.* 1988, Luu-The *et al.* 1989, Dumont *et al.* 1992). An in-tandem pseudogene of 17 β -HSD 1 has also been identified (Luu-The *et al.* 1990). Type 2 17 β -HSD is expressed in liver, placenta, endometrium and small intestine and converts E2 to E1, testosterone to androstenedione as well as the inactive progesterone, 20 α -dihydroprogesterone, to the active progesterone, progesterone (Wu *et al.* 1993). Type 3 17 β -HSD is an enzyme responsible for the conversion of the weak androgen androstenedione to the potent androgen testosterone, but it also catalyzes the conversion of dehydroepiandrosterone (DHEA) to androstenediol (Adiol) and E1 to E2 (Geissler *et al.* 1994). To date, it has been shown to be expressed only in the testes. Type 4 17 β -HSD is expressed in many tissues including liver, testis, ovary, prostate and heart, but not in placenta, and it preferentially inactivates E2 to E1 and also converts Adiol to DHEA (Adamski *et al.* 1995).

In the 1970s the presence of 17 β -HSD activity in human fetal and adult brain (Jenkins & Hall 1977) and rat brain (Rommerts & van der Molen 1971, Pérez *et al.* 1975) had been demonstrated in a few tissue specimens, but systematic studies on 17 β -HSD activity or expression of the mRNAs of 17 β -HSD isoforms in brain tissue are lacking.

The cloning of the cDNAs of the different 17 β -HSD isozymes has enabled this first investigation of the isozyme expression of 17 β -HSDs in the human brain. It was carried out on a large number of temporal lobe tissue specimens from children and adults to determine the predominant isoforms and to elucidate the existence of possible sex and age differences.

Subjects and Methods

Subjects

Biopsy materials removed at neurosurgery from 34 women (32.5 ± 1.3 years; mean $\pm$ S.E.M.), 32 men (34.8 ± 1.6 years) and 10 children (6 boys and 4 girls; 8 ± 1.4 years) with temporal lobe epilepsy undergoing partial temporal lobe resection were utilized. All patients received carbamazepine (CBZ) as monotherapy or as co-medication with one additional antiepileptic drug.

Tissues

Temporal lobe biopsy materials were separated into cortex and subcortical white matter by inspection and transferred into liquid nitrogen immediately after removal and stored at -80°C for further use. Cortex tissue specimens were available from 19 women, 16 men and 9 children, white matter tissue specimens from 6 women, 7 men and 1 child and both cerebral cortex and white matter tissue specimens from 9 women, 9 men and 1 child.

Liver tissue ($n=3$) was obtained from biopsies to exclude liver diseases in a transplantation program, and testis tissue ($n=4$) from patients with prostate carcinoma undergoing orchiectomy. Adrenal tissue ($n=4$) originated from tumoral kidneys. Placental tissue was obtained from six normal deliveries. Tissues were transferred to liquid nitrogen immediately after removal and stored at -80°C for further use.

The study was approved by the local ethics committee and informed consent was obtained from all tissue donors or their parents.

mRNA quantification

The mRNAs of 17 β -HSD 1, 2, 3 and 4 as well as the pseudogene of 17 β -HSD 1 were quantified with only a few modifications according to a nested competitive

reverse transcription (RT)-PCR protocol previously described (Watzka *et al.* 1997, Waha *et al.* 1998).

Total RNA was extracted from 25 to 50 mg tissue using the Trizol Reagent (Gibco-BRL, Paisley, Strathclyde, UK). Traces of DNA were removed by treatment with RNase-free DNase I (Boehringer-Mannheim, Mannheim, Germany) followed by a second RNA extraction. RNA was taken up in RNase-free water and quantified by its spectrophotometric absorption at 260 nm.

Competitive RNA standards were prepared by two-step mutagenesis of 17 β -HSD 3 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Watzka *et al.* 1997) or single-step mutagenesis of 17 β -HSD 1 and its pseudogene, 17 β -HSD 2 and 4 (Waha *et al.* 1998) resulting in the loss of 39, 23, 14, 13 and 27 bp for 17 β -HSD 1, 2, 3, 4 and the pseudogene of 17 β -HSD 1 respectively. Successful mutagenesis was confirmed by sequencing on a semiautomated sequencer (373A, Applied Biosystems, Foster City, CA, USA). 17 β -HSD 3 and GAPDH cDNAs were cloned with the pCR-script cloning kit (Stratagene, La Jolla, CA, USA). Standard RNAs for all investigated genes were produced by *in vitro* transcription using an RNA *in vitro* transcription kit (Stratagene) with T7 polymerase as previously described (Watzka *et al.* 1997, Waha *et al.* 1998).

To estimate the amount of standard RNA required for quantification of individual RNA samples, three to six RNA samples of the respective tissue groups were pooled. To aliquots of these mixtures containing 250 ng RNA each, defined amounts of standard RNAs were added. Serial dilutions ranged from 500 pg to 5 ag (attograms) for GAPDH and 100 pg to 1 ag for 17 β -HSD 1 and its pseudogene, 17 β -HSD 2, 3 and 4. Each mixture containing the respective amount of RNA standard and patient RNA was reverse transcribed followed by PCR amplification. The optimal titration point was defined as the concentration of standard RNA where PCR products yielded signals of comparable intensity for standard and native RNA (Fig. 1). A stock solution was prepared containing standard RNAs for 17 β -HSD 1 and its pseudogene, 17 β -HSD 2, 3, 4 and GAPDH at the optimal titration point. The concentration of this stock solution was selected in a way that 1 μl stock was sufficient for the RT of 250 ng total RNA. RT was performed at 42°C for 60 min using 100 U Superscript II (Superscript preamplification System, Gibco-BRL). Resulting cDNA was diluted 20-fold with water and for GAPDH, 17 β -HSD 2, 3 and 4 PCR was performed in a final volume of 20 μl containing 2 μl diluted cDNA, 10 mM Tris-HCl pH 8.3, 40 mM KCl, 1.5 mM MgCl_2 , 200 μM of each dNTP, 0.5 U Taq polymerase (Boehringer-Mannheim) and 4 pmol of each primer (Table 1). Primers were obtained from Genosys, Cambridge, UK or Applied Biosystems. Primers used for GAPDH have previously been published (Watzka *et al.* 1997). For 17 β -HSD 1 and its pseudogene,

Table 1 Primers used for amplification. f, forward primer; r, reverse primer; fn, nested forward primer; rn, nested reverse primer; mut, primer used for two-step mutagenesis or single-step mutagenesis; T7 f mut, primer used for single-step mutagenesis

17 β -HSD 1 f	GTCTTCCTCACCGCTTTGCGCGCC
17 β -HSD 1 r	GCACTGCGCCCGGCTCGTCCTC
17 β -HSD 1 fn	CGAAGCCGACCCTGCGCTACTTAC
17 β -HSD 1 rn	GCACTGCGCCCGGCTCGTCCTC
17 β -HSD 1 T7 f mut	GGATCCTAATACGACTCACTATAGGGAGGTCTTCTCACCGCTTTGCGCGCC
17 β -HSD 1 r mut	GCACTGCGCCCGGCTCGTCCTCGGCTTGGCCGAACGTC
17 β -HSD 1 pseudogene f	GTCTTCCTCACCGCTATGCGCGCC
17 β -HSD 1 pseudogene r	GTCTCCCATCCACCGGCCCCGC
17 β -HSD 1 pseudogene fn	CGAAGCCGACCCTGCGCTACTTAC
17 β -HSD 1 pseudogene rn	GTCTCCCATCCACCGGCCCCGC
17 β -HSD 1 pseudogene T7 f mut	GGATCCTAATACGACTCACTATAGGGAGGTCTTCTCACCGCTATGCGCGCC
17 β -HSD 1 pseudogene r mut	GTCTCCCATCCACCGGCCCCGCGCCTCGGCTCGGGATCGTC
17 β -HSD 2 f	CTCGGTGTCATGCTTCCTC
17 β -HSD 2 r	ATGAGAACATGGTCACAGCC
17 β -HSD 2 fn	GGTGAATGTCAGCAGCATGG JOE
17 β -HSD 2 rn	ATGAGAACATGGTCACAGCC
17 β -HSD 2 T7 f mut	GGATCCTAATACGACTCACTATAGGGAGTCTCGGTGTCATGCTTCCTC
17 β -HSD 2 r mut	ATGAGAACATGGTCACAGCCATAAGATGCCAGCCTTTC
17 β -HSD 3 f	TTCCAAGGCGTTTGTGTGGC
17 β -HSD 3 r	ACTCCTTTTCCAACACGACC
17 β -HSD 3 fn	AAGTCATCATCCAGGTGCTG JOE
17 β -HSD 3 rn	TACGGTGTCATCACACAGTCC
17 β -HSD 3 f mut	ACTGCTGATGATTGAATTATGTCACAATTGGAGGTG
17 β -HSD 3 r mut	TTAACTGTATTAAGTTTGAAGTAGTCGTCAGAACC
17 β -HSD 4 f	TCTCTCTTTTCTTGTGGC
17 β -HSD 4 r	TCAAACCTGCTAGACTAGC
17 β -HSD 4 fn	AAGTCAAGGTAGCTGTAGCC ROX
17 β -HSD 4 rn	TCAAACCTGCTAGACTAGC
17 β -HSD 4 T7 f mut	GGATCCTAATACGACTCACTATAGGGAGCTCTTCTTGTGGCTCTGG
17 β -HSD 4 r mut	TCAAACCTGCTAGACTAGCATGTGAAGGGATTCAGTC

Abbreviations for fluorescent dyes: JOE, 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein; ROX, 6-carboxy-X-rhodamine.

recombinant Pfu polymerase (Stratagene) instead of Taq polymerase was used. One primer of the primer pairs used for GAPDH PCR or nested PCR (17 β -HSD 2, 3 and 4) was labeled with fluorescent dye. For 17 β -HSD 1 and its pseudogene fluorescently labeled primers did not work due to the demanding primer sequences, which could not be avoided because of the highly homologous sequences. In these cases we used unlabeled primers, agarose gel electrophoresis (4%: agarose type I low electroendosmosis, Sigma, Deisenhofen, Germany, and NuSive agarose, FMC Bio Products, Rockland, ME, USA, 2% each). Standard and wild type PCR products were detected with GelDoc System 1000 (BioRad, München, Germany). PCR amplification was carried out in microtiter plates in an Unoblock (Biometra, Göttingen, Germany). Initial denaturation at 94 °C for 4 min was followed by 32 (GAPDH) or 35 (17 β -HSD 2, 3 and 4) PCR cycles. Cycling conditions were 94 °C for 35 s, 55 °C for 50 s and 72 °C for 90 s. A final extension step of 5 min at 72 °C was added. Nested PCR of 17 β -HSD 2, 3 and 4 was performed under the same conditions. For 17 β -HSD 1 and its pseudogene, the initial denaturation at 95 °C for 6 min was followed by 35 PCR cycles. Cycling conditions were

95 °C for 40 s, 62 °C for 45 s and 72 °C for 120 s. A final extension step of 5 min at 72 °C was added. Nested PCR was performed under the following conditions: initial denaturation at 95 °C for 6 min, 95 °C for 50 s, 60 °C for 45 s and 72 °C for 80 s with a final extension step of 5 min at 72 °C.

Fluorescently labeled PCR products were separated on 6% denaturing acrylamide gels (50% w/w urea, 19:1 acrylamide:bisacrylamide, 1 × TBE) and analyzed. Peak areas were calculated with the Genescan program (Applied Biosystems, Version 1.2.1). The ratio of native PCR product to standard PCR product was used for the differential determination of gene expression. Initial differences in the amounts of total RNA which were subjected to RT were corrected by calculating the ratios of native GAPDH PCR products to standard GAPDH PCR products.

Statistical analysis

Results were calculated as means $\pm$ s.e.m. The statistical difference between groups was calculated using the

Mann–Whitney U test. *P* values <0.05 were considered to reflect statistical significance.

Results

Determination of titration points for 17 β -HSD mRNAs in reference tissues and temporal lobe tissue

In order to validate our mRNA quantification protocol we determined the expression of 17 β -HSD mRNAs in placental tissue (17 β -HSD 1 and 2), testis tissue (17 β -HSD 3), liver tissue (17 β -HSD 4) and adrenal tissue (pseudogene of 17 β -HSD 1). Employment of competitive RT-PCR requires knowledge of the amount of standard RNA which yields a signal of approximately equal density when co-amplified with total RNA. The optimal titration point was 10 pg standard RNA for 17 β -HSD 1 based on 250 ng total RNA (Fig. 1). The equivalent titration points were 1 pg standard RNA for 17 β -HSD 2, 500 fg standard RNA for 17 β -HSD 3, 10 pg for 17 β -HSD 4 and 1 pg for the pseudogene of 17 β -HSD 1. In all tissues the optimal titration point for GAPDH was 250 pg standard RNA based on 250 ng total RNA (Fig. 1).

In the same manner the titration points of 17 β -HSD mRNAs in human temporal lobe tissue were determined. The optimal titration point was 1 fg standard RNA for 17 β -HSD 1 and 250 pg for GAPDH based on 250 ng total RNA, 10 fg standard RNA for 17 β -HSD 3 and 10 pg standard RNA for 17 β -HSD 4 (Fig. 1). For 17 β -HSD 2 and the pseudogene of 17 β -HSD 1 even an RNA standard amount of 1 ag did not yield a detectable fluorescence signal of native RNA (Fig. 1). Conclusively, their mRNAs are not expressed in the human temporal lobe, only illegitimate transcription was detectable when the standard RNA was omitted in the RT step.

These data show that in the human temporal lobe 17 β -HSD 1 mRNA concentrations were 10 000-fold lower than in the placenta, while 17 β -HSD 3 mRNA concentrations were 50-fold lower than in testis tissue and 17 β -HSD 4 concentrations were of the same magnitude as in liver tissue.

Expression of 17 β -HSD mRNAs in temporal lobe tissue from children and adults

17 β -HSD 1, 3 and 4 mRNA concentrations in the cerebral cortex did not differ significantly between men and women (Table 2). 17 β -HSD 3 and 4 mRNA concentrations were significantly higher in the subcortical white matter of adults than in cortex tissue ($P < 0.0002$; $P < 0.004$; Table 2) while these differences could not be observed in 17 β -HSD 1 mRNA expression. Mean 17 β -HSD 1, 3 and 4 mRNA concentrations in the cortex of children were lower than in adults, but as only a few cortex specimens from children were available a statistical analysis of the

mRNA expression in cortex tissue of adults and children was not carried out.

Discussion

Neurons and glial cells are capable of synthesizing various steroid hormones such as estrogens via CYP19_{AROM} (Naftolin 1994, Stoffel-Wagner *et al.* 1998a) or dihydrotestosterone via 5 α -reductase (Martini & Melcangi 1991, Stoffel-Wagner *et al.* 1998b). Over 20 years ago the presence of 17 β -HSD activity was demonstrated in a few human (Jenkins & Hall 1977) and rat brain tissue specimens (Rommerts & van der Molen 1971, Pérez *et al.* 1975). To date, systematic studies on 17 β -HSD activity or expression of the mRNAs of 17 β -HSD isoforms in brain tissue are lacking.

Four isozymes of 17 β -HSD (type 1, 2, 3 and 4) and an in-tandem pseudogene of the type 1 isoform with differential tissue distribution and biochemical differences have been identified in humans (Luu-The *et al.* 1989, 1990, Dumont *et al.* 1992, Wu *et al.* 1993, Geissler *et al.* 1994, Adamski *et al.* 1995).

Although brain tissue homogenates are able to interconvert androstenedione to testosterone as well as E1 to E2 (Martel *et al.* 1992, 1994), the activity and substrate specificity of each isozyme of 17 β -HSD are greatly influenced by the *in vitro* conditions used for the assay, particular cofactor addition and the pH of the incubation. Thus, to determine which isozymes are present within a tissue, investigations on the presence of activity should be followed by an examination of mRNA for the different 17 β -HSD isozymes.

The present study is the first to determine the expression of 17 β -HSD isoforms in a large number of fresh human temporal lobe tissue specimens. The sensitive competitive RT-PCR approach used permitted us to demonstrate the expression of 17 β -HSD type 1, 3 and 4 in the human temporal lobe, but the pseudogene of the type 1 isoform and 17 β -HSD type 2 were not expressed.

A previous study, using Northern blot analysis (Casey *et al.* 1994), demonstrated that 17 β -HSD type 2 mRNA was not present in the human brain, a finding which is now confirmed by RT-PCR.

Previously, the presence of type 1 17 β -HSD primarily catalyzing the interconversion of E1 and E2 with a predominance of the reductive pathway was demonstrated in the rat, frog and human fetal brain using immunocytochemical techniques (Milewich *et al.* 1990, Pelletier *et al.* 1995, Mensah-Nyagan *et al.* 1996). We found that also in the human temporal lobe 17 β -HSD type 1 is expressed with mRNA concentrations about 10 000-fold lower than in the placenta.

Our system for quantification of 17 β -HSD 1 was primarily designed to distinguish between 17 β -HSD 1 and its pseudogene and different splicing variants cannot

Figure 1 Titration of RNA standards for 17 β -HSD 1 and its pseudogene, 17 β -HSD 2, 3 and 4. PCR was performed from total RNA of temporal lobe tissue (left lane) and reference tissues (right lane): placental tissue (17 β -HSD 1 and 2), testis tissue (17 β -HSD 3), liver tissue (17 β -HSD 4) and adrenal tissue (pseudogene of 17 β -HSD 1). Each lane corresponds to cDNA reversely co-transcribed from 250 ng total RNA with decreasing standard RNA concentrations of the respective 17 β -HSD isozymes. The amounts of standard RNAs were from left to right: 100 pg, 10 pg, 1 pg, 100 fg, 10 fg, 1 fg, 100 ag, 10 ag and 1 ag.

be differentiated. Thus, we cannot exclude that different splicing variants occur in temporal lobe or placenta tissue.

The individual levels of 17 β -HSD 1 mRNA vary considerably. This is due to a few individuals presenting very high expression levels. We have no good explanation

Table 2 Expression of 17β HSD 1, 17β HSD 3 and 17β HSD 4 mRNAs in the human temporal lobe. Data are expressed as means ± S.E.M. in arbitrary units

	17β HSD 1	17β HSD 3	17β HSD 4
Tissue			
Adults, cortex	2525 ± 398 (n=51)	5428 ± 1057 (n=53)	675 ± 74 (n=53)
Adults, swm	3860 ± 1628 (n=28)	14 591 ± 3457* (n=31)	1201 ± 212** (n=31)
Children, cortex	1237 ± 403 (n=7)	3395 ± 1506 (n=9)	359 ± 86 (n=10)
Women, cortex	2350 ± 459 (n=28)	7041 ± 1909 (n=28)	584 ± 74 (n=28)
Women, swm	5933 ± 3431 (n=13)	11 534 ± 2459*** (n=15)	1184 ± 204**** (n=15)
Men, cortex	2739 ± 691 (n=23)	3620 ± 53 (n=25)	777 ± 133 (n=25)
Men, swm	2064 ± 543 (n=15)	17 457 ± 6315***** (n=16)	1218 ± 371**** (n=16)

swm: subcortical white matter.
*P<0.0002, swm vs cortex tissue, **P<0.004, swm vs cortex tissue, ***P<0.01, swm vs cortex tissue,
****P<0.05, swm vs cortex tissue, *****P<0.002, swm vs cortex tissue.

for the runaways; regional differences within the temporal lobe itself might account for them.

17β-HSD type 3 concentrations were 50-fold lower in the temporal lobe than in testis tissue. To date, the presence of 17β-HSD type 3 mRNA in brain tissue has not been reported. Since in the brain of rats and rhesus monkeys (Rommerts & van der Molen 1971, Pérez *et al.* 1975, Martel *et al.* 1994), as well as in human temporal lobe specimens (Steckelbroeck *et al.* 1997), androstenedione can be converted to testosterone, these interconversions may be associated with the type 3 isoform. However, in a study using Northern blot analysis the expression of 17β-HSD 3 was not detected in the human brain, but only in the testes (Geissler *et al.* 1994). This discrepancy probably results from either the 50-fold lower expression of this isoform in the temporal lobe compared with testis tissue reaching the borders of sensitivity of Northern blot analysis, or from differences in the brain region under investigation. These, however, were not further identified by Geissler and his coworkers.

Type 4 17β-HSD was also expressed in the human temporal lobe with mRNA concentrations of the same magnitude as in liver tissue. Northern blot analysis of 17β-HSD type 4 in various human tissues, including brain tissue, revealed a widespread expression of the enzyme (Adamski *et al.* 1995). The formation of E1 from E2 has been demonstrated in various rat tissues including the brain (Martel *et al.* 1992). This interconversion may be associated with 17β-HSD type 4, as 17β-HSD type 2 mRNA was not expressed in the brain.

The expression of 17β-HSD 1, 3 and 4 in the temporal lobe did not differ between sexes. 17β-HSD 4 concentrations were lower in the cortex of children than in that of adults. 17β-HSD 4 activity favors the oxidation of the most potent estrogen E2 to the weak estrogen E1 so as to inactivate estrogens. Recently, we demonstrated in the same tissue specimens that CYP19_{AROM} expression is significantly lower in the cortex of children than in that of adults (Stoffel-Wagner *et al.* 1998a). Thus, in children local E2 formation from testosterone via CYP19_{AROM} might be lower than in adults and this might reduce the need for an enzyme that inactivates E2.

In the subcortical white matter of adults, 17β-HSD 3 and 4 mRNA concentrations were significantly higher than in cortex tissue, whereas for 17β-HSD 1 mRNA expression this difference did not reach significance. Recently we demonstrated in a few human temporal lobe specimens that the conversion of androstenedione to testosterone was significantly higher in the subcortical white matter than in cortex tissue of both men and women (Steckelbroeck *et al.* 1997). These data support the finding of higher 17β-HSD 3 mRNA levels in white matter than in cortex tissue. In the rat and frog brain, 17β-HSD 1-immunoreactive material appeared to be present only in glial and ependymal cells (Pelletier *et al.* 1995, Mensah-Nyagan *et al.* 1996). 17β-HSD 3 and 4 immunoreactivity have not been studied to date. Our data confirm the predominant 17β-HSD expression in non-neural cells and suggest that glial cells could play an important role in the biosynthesis and inactivation of sex steroid hormones. On

the other hand, glial cells are involved in the formation of myelin, suggesting a possible correlation between sex steroids, these enzymatic activities and the formation of myelin, or with its functions.

The importance of 17 β -HSDs in the maintenance of physiological levels of E2 or testosterone is supported by its ubiquitous distribution in the human (Martel *et al.* 1992, 1994). The expression and regulation of the counteracting enzymes CYP19_{AROM} and 17 β -HSD 1 on the one hand and 17 β -HSD 4 on the other hand in the human temporal lobe might well determine the estrogenic microenvironment and may be important in terms of intracrine and paracrine effects in the brain. The brain might possess the ability to adjust the rate of sex steroid formation according to its individual needs.

Temporal lobe specimens used for our study were from patients who were treated with either CBZ as monotherapy or as co-medication with another antiepileptic drug. It has been reported that CBZ interacts competitively with enzymes of the cytochrome P450 superfamily such as CYP17 in testicular tissue (Kühn-Velten *et al.* 1990); effects on the mRNA expression of these enzymes or on the expression as well as the activity of 17 β -HSDs have not yet been reported. If there is an unknown effect of CBZ on the mRNA expression of 17 β -HSDs in the brain, it would be the same for all subjects under investigation.

In conclusion, the present study demonstrates for the first time the expression of 17 β -HSD 1, 3 and 4 mRNAs in a large number of temporal lobe specimens from children and adults, but 17 β -HSD 2 mRNA and the pseudogene of 17 β -HSD 1 were not expressed. Together with CYP19_{AROM} and 5 α -reductase, which are known to be expressed in the human brain, the expression of 17 β -HSD 1, 3 and 4 mRNAs indicates the major importance of local steroid biosynthesis in the brain.

Acknowledgements

This work was supported by the Deutsche Forschungsgemeinschaft by grant Kl 524/4–1. We thank Prof. M Nuri, Waldkrankenhaus Bonn, Department of Urology, for supply of testis tissue, Dr P Albers, University of Bonn, Department of Urology, for supply of adrenal tissue, Dr R K Schmutzler, University of Bonn, Department of Gynecology and Obstetrics, for supply of placental tissue, and Dr M Wolff, University of Bonn, Department of Surgery, for supply of liver tissue.

References

- Adamski J, Normand T, Leenders F, Monté D, Begue A, Stéhelin D, Jungblut PW & De Launoit Y 1995 Molecular cloning of a novel widely expressed human 80 kDa 17 β -hydroxysteroid dehydrogenase IV. *Biochemical Journal* **311** 437–443.
- Casey ML, MacDonald PC & Andersson S 1994 17 β -Hydroxysteroid dehydrogenase type 2: chromosomal assignment and progesterin regulation of gene expression in human endometrium. *Journal of Clinical Investigation* **94** 2135–2141.
- Dumont M, Luu-The V, De Launoit Y & Labrie F 1992 Expression of human 17 β -hydroxysteroid dehydrogenase in mammalian cells. *Journal of Steroid Biochemistry and Molecular Biology* **41** 605–608.
- Geissler WM, Davis DL, Wu L, Bradshaw KD, Patel S, Mendonca BB, Elliston KO, Wilson JD, Russell DW & Andersson S 1994 Male pseudohermaphroditism caused by mutations of testicular 17 β -hydroxysteroid dehydrogenase 3. *Nature Genetics* **7** 34–39.
- Jenkins JS & Hall CJ 1977 Metabolism of [¹⁴C]testosterone by human foetal and adult brain tissue. *Journal of Endocrinology* **74** 425–429.
- Kühn-Velten WN, Herzog AG & Müller MR 1990 Acute effects of anticonvulsant drugs on gonadotropin-stimulated and precursor-supported androgen production in the rat testis. *European Journal of Pharmacology* **181** 151–155.
- Lephart ED 1993 Brain 5 α -reductase: cellular, enzymatic, and molecular perspectives and implications for biological function. *Molecular and Cellular Neurosciences* **4** 473–484.
- Luu-The V, Labrie C, Zhao HF, Couet J, Lachance Y, Simard J, Leblanc G, Côté J, Bérubé D, Gagné R & Labrie F 1989 Characterization of cDNAa for human estradiol 17 β -dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5'-termini in human placenta. *Molecular Endocrinology* **3** 1301–1309.
- Luu-The V, Labrie C, Simard J, Lachance Y, Zhao H-F, Couet J, Leblanc G & Labrie F 1990 Structure of two in tandem human 17 β -hydroxysteroid dehydrogenase genes. *Molecular Endocrinology* **4** 268–275.
- Martel C, Rhéaume E, Takahashi M, Trudel C, Couet, Luu-The V, Simard J & Labrie F 1992 Distribution of 17 β -hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues. *Journal of Steroid Biochemistry and Molecular Biology* **41** 597–603.
- Martel C, Melner MH, Gagné D, Simard J & Labrie F 1994 Widespread tissue distribution of steroid sulfatase, 3 β -hydroxysteroid dehydrogenase/ Δ^5 - Δ^4 isomerase (3 β -HSD), 17 β -HSD 5 α -reductase and aromatase activities in the rhesus monkey. *Molecular and Cellular Endocrinology* **104** 103–111.
- Martini L & Melcangi RC 1991 Androgen metabolism in the brain. *Journal of Steroid Biochemistry and Molecular Biology* **39** 819–828.
- Mensah-Nyagan AM, Feuilloley M, Do-Rego JL, Marcual A, Lange C, Tonon MC, Pelletier G & Vaudry H 1996 Localization of 17 β -hydroxysteroid dehydrogenase and characterization of testosterone in the brain of the male frog. *Proceedings of the National Academy of Sciences of the USA* **93** 1423–1428.
- Milewich L, Carr BR, Frenkel RA, Marrero H, MacDonald PC & Mason JI 1990 17 β -Hydroxysteroid oxidoreductases of human fetal and adult tissues: immunological cross-reactivity with an anti-human placental cytosolic 17 β -hydroxysteroid oxidoreductase antibody. *Placenta* **11** 95–108.
- Naftolin F 1994 Brain aromatization of androgens. *Journal of Reproductive Medicine* **39** 257–261.
- Pelletier G, Luu-The V & Labrie F 1995 Immunocytochemical localization of type I 17 β -hydroxysteroid dehydrogenase in the rat brain. *Brain Research* **704** 233–239.
- Peltoketo H, Isomaa V, Möntäusta O & Vihko R 1988 Complete amino acid sequence of human placental 17 β -hydroxysteroid dehydrogenase deduced from cDNA. *FEBS Letters* **239** 73–77.
- Pérez AE, Ortiz A, Cabeza M, Beyer C & Pérez-Palacios G 1975 *In vitro* metabolism of ³H-androstenedione by the male rat pituitary, hypothalamus and hippocampus. *Steroids* **25** 53–62.
- Rommerts FFG & van der Molen HJ 1971 Occurrence and localization of 5 α -steroid reductase, 3 α - and 17 β -hydroxysteroid dehydrogenase in hypothalamus and other brain tissues of the male rat. *Biochimica et Biophysica Acta* **248** 489–502.

- Sholl SA, Goy RW & Kim KL 1989 5 α -Reductase, aromatase, and androgen receptor levels in the monkey brain during fetal development. *Endocrinology* **124** 627–634.
- Simerly RB, Chang C, Muramatsu M & Swanson LW 1990 Distribution of androgen and estrogen receptor mRNA-containing cells in the rat brain: *in situ* hybridization study. *Journal of Comparative Neurology* **294** 76–95.
- Steckelbroeck S, Stoffel-Wagner B, Watzka M, Schramm J, Reichelt R, Bidlingmaier F, Schweikert HU & Klingmüller D 1997 Quantification of 17 β -hydroxysteroid dehydrogenase activity in human brain tissue. *79th Annual Meeting, The Endocrine Society, Minneapolis (USA)*, 11–14 June 1997, p 209 (Abstract P1–298).
- Stoffel-Wagner B, Watzka M, Steckelbroeck S, Schwaab R, Schramm J, Bidlingmaier F & Klingmüller D 1998a Expression of CYP19 (aromatase) mRNA in the human temporal lobe. *Biochemical and Biophysical Research Communications* **244** 768–771.
- Stoffel-Wagner B, Watzka M, Steckelbroeck S, Wickert L, Schramm J, Romalo G, Klingmüller D & Schweikert HU 1998b Expression of 5 α -reductase in the human temporal lobe of children and adults. *Journal of Clinical Endocrinology and Metabolism* **83** 3636–3642.
- Waha A, Watzka M, Koch A, Pietsch T, Przkora R, Peters N, Wiestler OD & von Deimling A 1998 A rapid and sensitive protocol for competitive reverse transcriptase (cRT) PCR analysis of cellular genes. *Brain Pathology* **8** 13–18.
- Watzka M, Waha A, Koch A, Schmutzler RK, Bidlingmaier F, von Deimling A, Klingmüller D & Stoffel-Wagner B 1997 An optimized protocol for mRNA quantification using nested competitive RT-PCR. *Biochemical and Biophysical Research Communications* **231** 813–817.
- Wu L, Einstein M, Geissler WM, Chan HK, Elliston KO & Andersson S 1993 Expression cloning and characterization of human 17 β -hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 α -hydroxysteroid dehydrogenase activity. *Journal of Biological Chemistry* **268** 12964–12969.

Received 5 May 1998

Revised manuscript received 3 September 1998

Accepted 9 September 1998